ArticleBMC microbiology2026
Seroepidemiology and serotype diversity of foot-and-mouth disease virus in cattle and other domestic ungulates across Nigeria.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFoot-and-mouth disease (FMD) is a highly contagious viral infection of cloven-hoofed animals that causes substantial economic losses and severe disruptions to agricultural systems globally. It affects animal health and productivity in Nigeria but there is paucity of data across regions and among various animal species. This study determined the seroepidemiology and serotype diversity of the FMD virus (FMDV) among domestic ungulates including cattle, sheep, goats, and pigs, across all geopolitical zones in Nigeria. MATERIALS AND
methods1002 sera were collected aseptically from domestic ungulate animals (cattle n = 511, sheep n = 182, goat n = 218 and pigs n = 91) and were analysed using commercial ELISA kits (ID Vet®, France and IZLER®, Italy) to antibody and serotype-specific antibodies to FMD. Metadata on individual species were collected through questionnaire uploaded on Kobocollect containing sociodemographic data, and distribution of FMD in Nigeria.
resultsThe study revealed an overall FMD seroprevalence of 45.7% for all the various species and regions in Nigeria with specific host prevalence of 69.7% for cattle, 26.9% for sheep, 20.6% for goats, and 8.8% for pigs. Among the 458 FMD-seropositive samples, serotype O was the most predominant (74.9%), followed by A (56.3%), SAT 2 (35.8%), Asia 1 (22.9%) and SAT 1 (16.8%). Kaduna had the highest seroprevalence (88.9%), while Cross River had the lowest (9.1%). Multi-serotype infections were most common in cattle (32%). Health status and body condition were major determinants of susceptibility, with unhealthy animals being five times more likely to test positive for FMD (OR = 5.479, p < 0.001). While cattle constituted the majority of samples analysed, the inclusion of sheep, goats, and pigs provided comparative insights into interspecies variation in exposure and serotype occurrence.
conclusionWe have systematically determined FMDV seroprevalence and serotype distribution in various domestic ungulate species across all the geopolitical zones in Nigeria. Our findings reveal that serotype O and A remain dominant across Nigeria, while the unexpected detection of serotype Asia 1 indicates possible viral evolution or introduction from new sources. Furthermore, border proximity was not a significant predictor of infection, suggesting localized transmission dynamics. These insights underscore the need for improved surveillance, context-specific multivalent vaccination strategies, and further molecular investigation of emerging serotypes in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.